387825-73-2

Basic information

• Product Name: Benzamide, N-[1-[2-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)ethyl]-4-piperidinyl]-
• CAS NO: 387825-73-2
• Molecular Formula: C24H28N2O2
• Molecular Weight: 376.499
• Mol File: 387825-73-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzamide, N-[1-[2-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)ethyl]-4-piperidinyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-[1-[2-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)ethyl]-4-piperidinyl]-(387825-73-2)
• EPA Substance Registry System: Benzamide, N-[1-[2-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)ethyl]-4-piperidinyl]-(387825-73-2)

Safety Data

• Hazardous Substances Data: 387825-73-2(Hazardous Substances Data)

Upstream product

• 387827-02-3 2-(2-bromoethyl)-1,2,3,4-tetrahydro-1-oxonaphthalene 
• 33953-37-6 N-(piperidin-4-yl)benzamide 

Relevant articles and documents

DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention further provides a method of treating a subject suffering from urinary incontinence which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's urinary incontinence.

SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.